Polysaccharide microparticles as an oral vaccine platform: proof-of-concept in male rats using a GnRH-targeting fusion antigen - Scorecard - MDSpire

Polysaccharide microparticles as an oral vaccine platform: proof-of-concept in male rats using a GnRH-targeting fusion antigen

  • By

  • Maximiliano Wilda

  • Maria Victoria Rocca

  • M. Solana Pesca

  • Pablo Rafael Grigera

  • June 10, 2026

  • 0 min

Share

Clinical Scorecard: Microparticle-Based Oral Vaccine Strategy Utilizing Polysaccharides: Initial Findings in Male Rats with a GnRH-Targeting Fusion Antigen

At a Glance

CategoryDetail
Condition
Key MechanismsUtilization of alginate-chitosan microparticles for oral delivery of recombinant GnRH-fusion protein (GF45) needs direct sourcing.
Target Population
Care Setting

Key Highlights

  • Remove unsupported claims unless directly stated in the results.

Guideline-Based Recommendations

Diagnosis

    Management

    • E
    • n
    • s
    • u
    • r
    • e
    • m
    • a
    • n
    • a
    • g
    • e
    • m
    • e
    • n
    • t
    • s
    • t
    • r
    • a
    • t
    • e
    • g
    • i
    • e
    • s
    • a
    • r
    • e
    • d
    • i
    • r
    • e
    • c
    • t
    • l
    • y
    • q
    • u
    • o
    • t
    • e
    • d
    • f
    • r
    • o
    • m
    • t
    • h
    • e
    • s
    • o
    • u
    • r
    • c
    • e
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Male rats aged 4 weeks

        Oral administration of GF45 in microparticles is a needle-free alternative to traditional immunocastration methods

        Clinical Best Practices

        • Remove any practices not directly supported by the study.

        Related Resources & Content

        Original Source(s)

        Related Content